Ge Long Hui A P P·2025-08-27 07:49Core Viewpoint - Anke Biotech reported a decline in net profit for the first half of the year, primarily due to increased promotional and R&D expenses, despite stable revenue growth in its main business segment [1] Financial Performance - The company achieved a net profit attributable to shareholders of 367 million yuan, a year-on-year decrease of 11.92% [1] - The non-recurring net profit attributable to shareholders was 342 million yuan, down 12.38% year-on-year [1] - Revenue remained stable, with the main business segment of biological products generating 969 million yuan, reflecting a year-on-year growth of 7.49% [1] Product Development and Market Position - The company's first antibody drug, trastuzumab injection "Ansaiting," experienced rapid sales growth, with revenue increasing by 298% year-on-year, becoming a key driver of performance [1] - The company actively expanded its product matrix through business development collaborations, introducing two significant long-acting products during the reporting period [1] - The exclusive introduction of long-acting follicle-stimulating hormone strengthens the company's position in the assisted reproduction sector [1] Future Outlook - The company is viewed positively for its long-term development potential, maintaining a "buy" rating [1]